Advertisement


Noelle Cloven, MD, on RAINFOL-03: Actively Recruiting Trial in Pretreated Endometrial Cancer

ASCO 2026

Advertisement

Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigator’s choice of chemotherapy in patients with endometrial cancer after receipt of platinum-based chemotherapy and PD-L1 inhibition (Abstract TPS5646).



Related Videos

Leukemia

Michael G. Fradley, MD: How Does Atrial Fibrillation Affect Outcomes and Health-Care Utilization Among Patients With CLL?

Michael G. Fradley, MD, of the University of Pennsylvania School of Medicine, discusses findings from a study which evaluated impact of atrial fibrillation on cardiovascular outcomes (stroke, bleeding, heart failure) and health-care utilization in patients with chronic lymphocytic leukemia (CLL) overall, by age, and by treatment (Abstract 7042). 

Skin Cancer

Katharina C. Kaehler, MD, on Daromun in Resectable Locally Advanced Melanoma: Trial Updates

Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517). 

Lung Cancer

Tony S.K. Mok, MD, FRCPC, FASCO, on Advanced ALK-Positive NSCLC: 7-Year Update From the CROWN Trial

Tony S.K. Mok, MD, FRCPC, FASCO, of the Chinese University of Hong Kong, presents long-term findings from the CROWN trial, which evaluated lorlatinib vs crizotinib in patients with advanced ALK-positive non–small cell lung cancer (NSCLC). At 5 years, median progression-free survival was not reached with lorlatinib in this population, representing the longest progression-free survival ever reported in advanced NSCLC (Abstract 8502). 

Bladder Cancer

Ronald C. Chen, MD, MPH, FASCO, on High-Risk Muscle-Invasive Urothelial Carcinoma: HRQoL With Pembrolizumab vs Observation

Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, adjuvant pembrolizumab for 1 year approximately doubled disease-free survival, causes fatigue and dyspnea which modestly impacted physical function and ability to perform certain roles (such as work and hobbies), without impact on overall quality of life (Abstract 4513).

Immunotherapy

Suneel Kamath, MD, on Correlation Between Blood and Tissue Tumor Mutation Burden

Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580). 

Advertisement

Advertisement




Advertisement